메뉴 건너뛰기
Gut
Volumn 55, Issue 9, 2006, Pages 1362-1363
Disappointing results of combination therapy for HCV? [4]
Author keywords

[No Author keywords available]
Indexed keywords

PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN;
EID: 33747800025     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.094292     Document Type: Letter
Times cited : (12)
References (6)
  • 1
    • 0035934568 scopus 로고    scopus 로고
    • Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial
    • Manns MP, McHutchinson JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-65.
    • (2001) Lancet , vol.358 , pp. 958-965
    • Manns, M.P.1    McHutchinson, J.G.2    Gordon, S.C.3
  • 2
    • 0037179698 scopus 로고    scopus 로고
    • Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection
    • Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
    • (2002) N Engl J Med , vol.347 , pp. 975-982
    • Fried, M.W.1    Shiffman, M.L.2    Reddy, K.R.3
  • 3
    • 1542378867 scopus 로고    scopus 로고
    • Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: A randomised study of treatment duration and ribavirin dose
    • Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomised study of treatment duration and ribavirin dose. Ann Intern Med 2004;5:346-55.
    • (2004) Ann Intern Med , vol.5 , pp. 346-355
    • Hadziyannis, S.J.1    Sette Jr., H.2    Morgan, T.R.3
  • 4
    • 33747796168 scopus 로고    scopus 로고
    • Efficacy of PEG-IFN alfa-2b vs. PEG-IFN alfa-2a+ribavirin regimens in trealment-naïve chronic HCV patients: A cumulative meta-analysis of retrospective data from 6 clinical sites
    • Almasio PL, Cavalletto L, Chemello L, et al. Efficacy of PEG-IFN alfa-2b vs. PEG-IFN alfa-2a+ribavirin regimens in trealment-naïve chronic HCV patients: a cumulative meta-analysis of retrospective data from 6 clinical sites. Hepatology 2005;42(suppl 1):671 A.
    • (2005) Hepatology , vol.42 , Issue.SUPPL. 1
    • Almasio, P.L.1    Cavalletto, L.2    Chemello, L.3
  • 5
    • 33644559918 scopus 로고    scopus 로고
    • Weight-based ribavirin dosing (WBD) increases sustained virological response (SVR) in patients with chronic hepatitis C (CHC): Final results of the WIN-R study, a US community based trial
    • Jacobson IM, Brown RS, Freilich B, et al. Weight-based ribavirin dosing (WBD) increases sustained virological response (SVR) in patients with chronic hepatitis C (CHC): final results of the WIN-R study, a US community based trial. Hepatology 2005;42(suppl 1):749A.
    • (2005) Hepatology , vol.42 , Issue.SUPPL. 1
    • Jacobson, I.M.1    Brown, R.S.2    Freilich, B.3
  • 6
    • 33747765768 scopus 로고    scopus 로고
    • Pegetron prospective optimal weight-based dosing response program (POWER): Preliminary results
    • Abadir N, Marotta P, Feinman SV, et al. Pegetron prospective optimal weight-based dosing response program (POWER): preliminary results. Hepatology 2005;42(suppl 1):693A.
    • (2005) Hepatology , vol.42 , Issue.SUPPL. 1
    • Abadir, N.1    Marotta, P.2    Feinman, S.V.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.